Semanteon Capital Management LP Takes $561,000 Position in DaVita Inc. $DVA

Semanteon Capital Management LP acquired a new position in DaVita Inc. (NYSE:DVA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,223 shares of the company’s stock, valued at approximately $561,000.

Other hedge funds have also bought and sold shares of the company. Hantz Financial Services Inc. lifted its position in shares of DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares in the last quarter. MAI Capital Management grew its holdings in DaVita by 23.4% during the 2nd quarter. MAI Capital Management now owns 438 shares of the company’s stock valued at $62,000 after buying an additional 83 shares in the last quarter. NewEdge Advisors LLC lifted its holdings in shares of DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after buying an additional 88 shares in the last quarter. Teacher Retirement System of Texas boosted its position in shares of DaVita by 1.4% in the second quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock valued at $954,000 after acquiring an additional 94 shares during the period. Finally, Smartleaf Asset Management LLC grew its stake in DaVita by 34.9% during the third quarter. Smartleaf Asset Management LLC now owns 452 shares of the company’s stock valued at $59,000 after acquiring an additional 117 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on DVA. Barclays raised their price target on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. TD Cowen restated a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Truist Financial set a $158.00 price target on DaVita in a research report on Thursday, February 5th. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $155.80.

DaVita Trading Up 2.4%

NYSE DVA opened at $150.89 on Friday. The firm has a market cap of $10.08 billion, a PE ratio of 15.23, a price-to-earnings-growth ratio of 0.53 and a beta of 0.99. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $157.12. The stock has a 50-day moving average of $120.72 and a 200-day moving average of $125.17.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.24 by $0.16. The firm had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business’s revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.